subject: Womens Infertility - Drug Pipeline Analysis And Market Forecasts To 2016---aarkstore Enterprise [print this page] Womens Infertility - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
The industry analysis specialists new report, Womens Infertility Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global womens infertility market. The report identifies the key trends shaping and driving the global womens Infertility market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global womens infertility sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalDatas team of industry experts.
Scope
The report analyzes the opportunities and challenges for the global womens infertility disease market. It includes
- Annualized global womens infertility disease market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographic markets covered in this report are the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include GnRH antagonists, AMP-activated protein kinase (AMPK) agonists, luteinising hormone stimulators and Beta 2 receptor agonists.
- Analysis of the current and future competitors in the global womens infertility market. The key market players covered are Merck Serono SA, Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future womens infertility market.
